Annals of Hematology

, Volume 71, Issue 1, pp 35–39

Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients

Authors

  • P. K. MacCallum
    • Department of HematologySt. Bartholomew's Hospital
  • A. Z. S. Rohatiner
    • ICRF Department of Medical OncologySt. Bartholomew's Hospital
  • C. L. Davis
    • ICRF Department of Medical OncologySt. Bartholomew's Hospital
  • J. S. Whelan
    • ICRF Department of Medical OncologySt. Bartholomew's Hospital
  • A. M. Oza
    • ICRF Department of Medical OncologySt. Bartholomew's Hospital
  • J. Lim
    • ICRF Department of Medical OncologySt. Bartholomew's Hospital
  • S. Love
    • Medical Statistics LaboratoryImperial Cancer Research Fund
  • J. A. L. Amess
    • Department of HematologySt. Bartholomew's Hospital
  • M. Leahy
    • Department of HematologySt. Bartholomew's Hospital
  • R. K. Gupta
    • ICRF Department of Medical OncologySt. Bartholomew's Hospital
  • C. G. A. Price
    • ICRF Department of Medical OncologySt. Bartholomew's Hospital
  • T. A. Lister
    • ICRF Department of Medical OncologySt. Bartholomew's Hospital
Original Article

DOI: 10.1007/BF01696230

Cite this article as:
MacCallum, P.K., Rohatiner, A.Z.S., Davis, C.L. et al. Ann Hematol (1995) 71: 35. doi:10.1007/BF01696230

Abstract

The majority of patients with acute myeloid leukemia (AML) are elderly, and their response to chemotherapy is poorer than that of younger patients. The combination of mitoxantrone (MTN) and cytosine arabinoside (Ara-C) is a possible alternative to an anthracycline/Ara-C combination for the treatment of AML in these patients. Of 52 older patients (> 59 years) referred over a 3.5-year period, 33 patients (age range 60–78 years, median 67 years) received MTN and Ara-C as therapy for newly diagnosed AML. MTN was administered at a dose of 12 mg/m2/day, intravenously, for 3 days (23 patients), or 10 mg/m2/day for 5 days (10 patients), and Ara-C at a dose of 100 mg/m2 twice daily, intravenously, for 7 days. Complete remission (CR) was achieved in 16/33 patients (48%). The median remission duration was 6 months (range 1–37 months). The median survival was 14 months for those who achieved CR compared with 9 months for those with resistant disease. Two patients remain in first CR after 13 and 37 months, but three patients died whilst receiving consolidation therapy. In selected elderly patients with AML, the combination of MTN and Ara-C provides an acceptable alternative to an anthracycline/ Ara-C regimen, with a higher CR rate than historical controls. However, the CR rate and remission duration remain low compared with those of younger patients, supporting the need to investigate new approaches to treatment in this population.

Key words

Acute myeloid leukemiaCytosine arabinosideElderlyMitoxantrone

Copyright information

© Springer-Verlag 1995